


CLAIMS

1. A triazine derivative represented by the following formula (I):



(I)

wherein

R^1 represents a substituted or unsubstituted lower alkyl group,
 R^2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group,

A represents a nitrogen atom or C- R^3 ,

R^3 represents a hydrogen atom, cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group,

R^4 represents a substituted or unsubstituted lower alkyl group,
 a substituted or unsubstituted cycloalkyl group,
 or a pharmaceutically acceptable salt thereof.


2. A triazine derivative according to Claim 1,
 wherein

R^1 represents $-\text{CH}_2\text{OR}^5$,

R^5 represents a substituted or unsubstituted acyl group,
 or a pharmaceutically acceptable salt thereof.

Claims

1. A triazine derivative represented by the following formula (I):



wherein

R^1 is a substituted or unsubstituted lower alkyl group,

R^2 is a hydrogen atom or a substituted or unsubstituted lower alkyl group,

A is a nitrogen atom or C- R^3 ,

R^3 is a hydrogen atom, cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and

R^4 is a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted cycloalkyl group,

or a pharmaceutically acceptable salt thereof.

2. The triazine derivative according to Claim 1, wherein

R^1 is $-\text{CH}_2\text{OR}^5$, and

R^5 is a substituted or unsubstituted acyl group,
or a pharmaceutically acceptable salt thereof.

3. The triazine derivative according to claim 1, wherein

R^1 is a hydroxymethyl group,
or a pharmaceutically acceptable salt thereof.

4. The triazine derivative according to claim 1, wherein R^4 is a substituted or unsubstituted cycloalkyl group,
or a pharmaceutically acceptable salt thereof.

5. The triazine derivative according to claim 4, wherein R^4 is a cyclopropyl group,
or a pharmaceutically acceptable salt thereof.


6. The triazine derivative according to claim 1, wherein R^2 is a methyl group,
or a pharmaceutically acceptable salt thereof.


7. The triazine derivative according to claim 1, wherein R^2 is a hydrogen atom,
or a pharmaceutically acceptable salt thereof.

8. The triazine derivative according to claim 1, wherein A is a nitrogen atom,
or a pharmaceutically acceptable salt thereof.


9. The triazine derivative according to claim 1, wherein A is a $C-R^3$, or a pharmaceutically acceptable salt thereof.


10. A compound selected from the group consisting of:





11. A compound selected from the group consisting of:





or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the triazine derivative according to any one of claims 1 to 9, the compound according to claim 10 or 11, or a pharmaceutically acceptable salt thereof.

13. A method of inhibiting a Bruton's tyrosine kinase activity in a cell, comprising administering to the cell the triazine derivative according to any one of claims 1 to 9, the compound according to claim 10 or 11, or a pharmaceutically acceptable salt thereof.

14. Use of a pharmaceutical composition according to claim 12 in the preparation of a medicament for treating a disease related to an abnormal cell response through a Bruton's tyrosine kinase in a subject in need thereof.

15. Use according to claim 14, wherein the disease is selected from the group consisting of self-immune diseases, inflammatory diseases, bone diseases, cancer, lymphoma, and arthritis.

16. Use of a triazine derivative according to any one of claims 1 to 9, or a compound according to claim 10 or claim 11, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease related to an abnormal cell response through a Bruton's tyrosine kinase in a subject in need thereof.

17. Use according to claim 16, wherein the disease is selected from the group consisting of self-immune diseases, inflammatory diseases, bone diseases, cancer, lymphoma, and arthritis.

18. A pharmaceutical composition according to claim 12 for use in treating a disease related to an abnormal cell response through a Bruton's tyrosine kinase in a subject in need thereof.

19. The pharmaceutical composition according to claim 18, wherein the disease is selected from the group consisting of self-immune diseases, inflammatory diseases, bone diseases, cancer, lymphoma, and arthritis.

20. A compound selected from the group consisting of a triazine derivative according to any one of claims 1 to 9, a compound according to claim 10 or claim 11, and a pharmaceutically acceptable salt thereof, for use in treating a disease related to an abnormal cell response through a Bruton's tyrosine kinase in a subject in need thereof.

21. The compound according to claim 20, wherein the disease is selected from the group consisting of self-immune diseases, inflammatory diseases, bone diseases, cancer, lymphoma, and arthritis.